New Product: Approval Granted for Beilu Pharmaceutical's Enteric-coated Prolonged-release Paroxetine Hydrochloride Tablets

Recently, Beilu Pharmaceutical received a Drug Registration Certificate from the National Medical Products Administration for Paroxetine Hydrochloride Enteric-Coated Sustained-Release Tablets with a specification of 25mg (calculated as C₁₉H₂₀FNO₃).

The approval of Paroxetine Hydrochloride Enteric-Coated Sustained-Release Tablets as a Category 4 chemical drug, considered equivalent to passing the quality and efficacy consistency evaluation for generic drugs, will further enrich Beilu Pharmaceutical company's psychoneurotic product line and help enhance the market competitiveness of the company's products. The company will actively carry out various preparations for the launch of the new product and aim to bring the product to market as soon as possible.